The Association Between Polypharmacy and Mortality in Patients with Heart Failure: Results from the PULSE Dataset
Zusammenhang zwischen Polypharmazie und Mortalität bei Patient:innen mit Herzinsuffizienz: Ergebnisse aus dem PULSE-Datensatz
ESC Heart Failure · 01.12.2025 · 12 (6) · 4316-4325
DOI: 10.1002/ehf2.15445 ↗Auf einen Blick
In einer retrospektiven Kohortenstudie mit 660 Patient:innen mit Herzinsuffizienz war Polypharmazie nach der Hospitalisierung mit Mortalität assoziiert, vor allem bei HFrEF. Nach strenger Anpassung blieb der Zusammenhang nicht in allen Analysen bestehen.
Fragestellung
Besteht bei Patient:innen mit Herzinsuffizienz ein Zusammenhang zwischen Polypharmazie und Mortalität nach Hospitalisierung?
Methode
Retrospektive longitudinale Beobachtungskohorte; Medikationsdaten bei Aufnahme und Entlassung der ersten Herzinsuffizienz-Hospitalisierung; Analyse mit Cox-Modellen und inverse probability weighting.
Ergebnisse
660 Patient:innen, mittleres Alter 76,1 Jahre, 56 % männlich; fast 60 % waren am Studienende verstorben. Bei HFrEF war Hyperpolypharmazie in der univariablen Analyse mit höherer Mortalität verbunden (HR 1,95; 95 %-KI 1,36–2,82).
Schlussfolgerung der Autor:innen
Alter, Geschlecht, CCI und CFS waren starke Mortalitätsprädiktoren. Nach gründlicher Confounder-Anpassung war Polypharmazie nach Hospitalisierung bei HFrEF mit Mortalität assoziiert, bei HFpEF nicht.
Kernaussagen
- 660 Patient:innen mit Herzinsuffizienz, mediane Nachbeobachtung 2,9 Jahre
- HFrEF: Hyperpolypharmazie mit höherer Mortalität assoziiert
- HFpEF: kein Zusammenhang zwischen Hyperpolypharmazie und Mortalität
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Beobachtungsstudie in der Zeitschrift ESC Heart Failure, online erschienen am 11.10.2025. Verfasst von Janine Beezer und 4 weiteren Autor:innen. Beteiligte Einrichtung: South Tyneside and Sunderland Foundation Trust, Sunderland Royal Hospital, Sunderland, UK. Hauptthemen laut MEDLINE: Polypharmacy, Heart Failure, Stroke Volume. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: British Society for Heart Failure, Pharmacy Research UK.
Themen: Herzinsuffizienz, Medikationssicherheit
Abstract (Originalsprache)
Aims
Mortality remains high in heart failure despite advances in heart failure therapy. Heart failure patients are generally older, with multiple long-term conditions, and polypharmacy is common. This study explores the association between polypharmacy and mortality.
Methods
This retrospective longitudinal observational cohort study collected medication data on admission and discharge from the first heart failure hospitalisation. Association with mortality was explored using Cox proportional hazard models and inverse probability weighting regression analysis.
Results
A total of 660 patients were included, 367 (56%) male, mean age 76.1 (SD ±12.3) and almost 60% (338/660) had died at study end. Median follow-up time was 2.9 years (25th and 75th quartiles 1.6 and 4.5). It was rare to be discharged from hospital with no polypharmacy (5%, n = 31). Heart failure with preserved ejection fraction (HFpEF) was associated with a 32% (HR 1.32, CI 1.08–1.61, P = 0.007) higher mortality compared to HFrEF. In those with heart failure with reduced ejection fraction (HFrEF), univariable analysis showed hyperpolypharmacy was associated with twice the mortality compared to polypharmacy (HR 1.95, CI 1.36–2.82, P < 0.001). In multivariable analysis, the association between polypharmacy and mortality was lost. The average treatment effect for hyperpolypharmacy was associated with 26% (Coeff. −0.26, CI −0.43 to −0.09, P = 0.003) higher mortality than polypharmacy. The chance of survival to the end of follow-up was 80% (Coeff. 0.80, CI 0.64–0.95, P < 0.01) for those with polypharmacy, and 54% (Coeff. 0.54, CI 0.46–0.61, P < 0.01) for those with hyperpolypharmacy. In HFpEF, hyperpolypharmacy, univariable analysis was not associated with mortality (HR 0.93, CI 0.70–1.24, P = 0.63). Average treatment effect also showed that hyperpolypharmacy was not associated with mortality (Coeff. −0.03, CI −0.15 to 0.08, P = 0.55). The chance of survival to the end of follow-up was 67% (Coeff. 0.67, CI 0.58–0.77, P < 0.01) with polypharmacy and 64% (Coeff. 0.64, CI 0.57–0.71, P < 0.01) with hyperpolypharmacy.
Conclusions
Age, sex, CCI, and CFS are strong mortality predictors for HF irrespective of HF subgroup. Rigorous confounding adjustment suggests polypharmacy is associated with mortality following hospitalisation for HFrEF but not HFpEF. Further studies are needed to address the complex interplay between polypharmacy, age, comorbidity, and frailty.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- South Tyneside and Sunderland Foundation Trust, Sunderland Royal Hospital, Sunderland, UK.
- School of Pharmacy, The Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK.
- Hull University Teaching Hospitals NHS Trust, Castle Hill Hospital, Cottingham, UK.
- School of Pharmacy, The Faculty of Medical Sciences, Newcastle NIHR Patient Safety Collaboration (PSRC), Newcastle University, Newcastle upon Tyne, UK.
- Population Health Sciences Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK.
ORCID-Profile: Janine Beezer, Andrew L Clark, Adam Todd, Andrew Kingston, Andrew Husband
Förderung
- British Society for Heart Failure
- Pharmacy Research UK
Zitieren
APA
Beezer, J., Clark, A. L., Todd, A., Kingston, A., & Husband, A. (2025). The Association Between Polypharmacy and Mortality in Patients with Heart Failure: Results from the PULSE Dataset. ESC Heart Failure, 12(6), 4316-4325. https://doi.org/10.1002/ehf2.15445
Vancouver
Beezer J, Clark AL, Todd A, Kingston A, Husband A. The Association Between Polypharmacy and Mortality in Patients with Heart Failure: Results from the PULSE Dataset. ESC Heart Failure. 2025;12(6):4316-4325. doi:10.1002/ehf2.15445
BibTeX
@article{Beezer2025,
author = {Beezer, Janine and Clark, Andrew L and Todd, Adam and Kingston, Andrew and Husband, Andrew},
title = {The Association Between Polypharmacy and Mortality in Patients with Heart Failure: Results from the PULSE Dataset},
journal = {ESC Heart Failure},
year = {2025},
volume = {12},
number = {6},
pages = {4316--4325},
doi = {10.1002/ehf2.15445}
}
EUVIMED